Changes in Economic Conditions, Political Situations and Laws and Regulations in Overseas Markets
First written in FY2016. 10 of 29 entries say "Restated". Latest entry: FY2026.
Terumo moved to the "Worse" side of this theme in 2026, 5 years after the typical company in this theme (2021).
The whole theme swung hardest in 2025: 47 of 94 companies on the "Worse" side.
39 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Geopolitical risks, including those arising from the situation in the Middle East, have also increased, creating an uncertain outlook.」
Regarding political and external-environment risks in overseas markets, the increase in geopolitical risks, including the situation in the Middle East, was explicitly identified as a source of uncertainty in the outlook for the next period. - 2026-05-15WorsenedEarnings
「Geopolitical risks, including those arising from the situation in the Middle East, have also increased, creating an uncertain outlook.」
The Company newly identified heightened geopolitical risk as a risk surrounding its overseas business. - FY2025-H1MitigatedAnnual report
「During the current interim consolidated accounting period (1 April 2024 to 30 September 2024), global demand for products increased, exchange rates also contributed, and the Group's sales were strong.」
Sales remained strong due to increased global demand for products, and demand conditions in overseas markets continue to be described as having eased. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year (1 April 2023 to 31 December 2023), global demand for products increased, exchange rates also contributed, and the Group's sales were strong.」
The Company stated that sales were strong due to increased global demand for products and the contribution from exchange rates, and continued to describe demand conditions in overseas markets as having eased. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year (1 April 2023 to 30 September 2023), global demand for products increased, exchange rates also contributed, and the Group's sales were strong.」
The Company stated that sales were strong due to increased global demand for products and the contribution from exchange rates, and continued to describe demand conditions in overseas markets as having eased. - FY2024-Q1MitigatedAnnual report
「During the cumulative first quarter of the current consolidated fiscal year, global demand for products increased, exchange rates also contributed, and the Group's sales were strong.」
Global demand for products increased, and overseas sales revenue also rose 13.8% year on year. Demand conditions in overseas markets have remained relatively favorable compared with the previous fiscal year. - FY2023-Q3MitigatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, healthcare demand, which had declined due to the spread of COVID-19 in the previous fiscal year, recovered, and exchange rates also contributed, resulting in generally strong sales by the Group.」
Healthcare demand, which had declined in the previous fiscal year, recovered, and the impact of market conditions, including overseas markets, eased from the previous fiscal year. Recovery in Japan was delayed by the eighth wave of COVID-19, but overseas sales revenue increased 25.1%. - FY2023-Q2MitigatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, healthcare demand, which had declined due to the spread of COVID-19 in the previous fiscal year, recovered, and exchange rates also contributed, resulting in generally strong sales by the Group.」
Healthcare demand, which had declined in the previous fiscal year, recovered, and sales were generally strong, supported also by exchange rates. - FY2023-Q1MitigatedAnnual report
「Healthcare demand, which had declined due to the spread of COVID-19 in the previous fiscal year, recovered, and the Group's sales were generally strong.」
Healthcare demand, which had declined due to the spread of COVID-19, recovered, and sales were generally strong. Overseas sales revenue increased 20.3% year on year, and demand conditions in overseas markets eased from the previous fiscal year. - FY2022MitigatedAnnual report
「Sales revenue for the current fiscal year was strong as demand in the Cardiovascular field, which had declined due to the impact of COVID-19, recovered overseas, particularly in Europe and the United States.」
The recovery in healthcare demand continued, particularly in North America and Europe, as postponed procedures, tests and diagnoses, and hospital admissions increased, and demand conditions in overseas markets eased from the previous fiscal year. - FY2022-Q3MitigatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, the recovery in healthcare demand from the impact of COVID-19 observed in the first quarter continued, and sales by the Group were generally strong.」
The recovery trend in healthcare demand, including overseas demand, from the impact of COVID-19 continued through the cumulative FY2022-Q3 period, and sales were generally strong. - FY2022-Q2MitigatedAnnual report
「The impact of the COVID-19 outbreak that began in the previous fiscal year was substantially alleviated, particularly in North America and Europe, and healthcare demand recovered as COVID-19 vaccines became more widely available, elective procedures that had been postponed across various medical specialties were performed, and tests, diagnoses and hospital admissions increased.」
The impact of COVID-19 on healthcare demand was substantially alleviated, particularly in North America and Europe, and demand recovered as elective procedures, tests and diagnoses, and hospital admissions increased. - FY2022-Q1MitigatedAnnual report
「During the first quarter of the current consolidated cumulative period (1 April 2021 to 30 June 2021), the impact of the COVID-19 outbreak that began in the previous fiscal year was substantially alleviated in the medical market. Particularly in North America and Europe, as COVID-19 vaccines became more widely available, healthcare demand recovered through the performance of elective procedures that had been postponed across various medical specialties, as well as increases in tests, diagnoses and hospital admissions.」
The impact of the COVID-19 outbreak was substantially alleviated, particularly in North America and Europe, and healthcare demand recovered as elective procedures, tests and diagnoses, and hospital admissions increased. - FY2021MaterialisedAnnual report
「Overseas, although the spread of COVID-19 had a limited impact on the Hospital Company and Blood and Cell Technologies Company, it had a significant impact on the Cardiovascular Company, particularly the TIS (catheter) business, resulting in a 4.7% decline in revenue from the previous fiscal year.」
External risks related to demand and economic conditions in overseas markets materialized over the full year as a 4.7% decline in overseas sales revenue, centered on the Cardiovascular business. - FY2021-Q3WorsenedAnnual report
「The adjustment amount of negative ¥2,458 million includes an inventory adjustment of ¥413 million, preparation costs of negative ¥1,762 million associated with compliance with the European Medical Device Regulation (MDR), and other items.」
Preparation costs for compliance with the European MDR totaled ¥1,762 million for the cumulative third quarter, up from ¥1,189 million in the previous disclosure. The burden of responding to overseas regulatory requirements is increasing. - FY2021-Q2MaterialisedAnnual report
「The adjustment amount of negative ¥1,355 million includes an inventory adjustment of ¥385 million, preparation costs of negative ¥1,189 million associated with compliance with the European Medical Device Regulation (MDR), and other items.」
Regarding the risk of changes to overseas laws and regulations, ¥1,189 million in preparation costs for compliance with the European MDR was recorded as an adjustment item in adjusted operating profit. - FY2021-Q1MaterialisedAnnual report
「During the first quarter of the current consolidated cumulative period (1 April 2020 to 30 June 2020), the medical market was significantly affected by the spread of COVID-19, particularly in April and May. Demand declined across various medical specialties due to the postponement of elective procedures, fewer tests and diagnoses, and shorter hospital stays.」
Regarding risks to healthcare demand and market conditions, including overseas markets, the COVID-19 outbreak materialized in April and May as postponed elective procedures, fewer tests and diagnoses, and shorter hospital stays. Overseas sales revenue decreased 18.4% year on year. - FY2020MaterialisedAnnual report
「Overseas, although the business slowed in the fourth quarter due to the impact of the COVID-19 outbreak, mainly in the TIS business in China, sales revenue at the Cardiovascular Company increased 6.7% year on year to ¥350.6 billion, driven by products including WEB, a device for saccular intracranial aneurysms in the neurovascular business.」
Regarding external-environment risks in overseas markets, including economic conditions, political conditions and regulations, the COVID-19 outbreak materialized as a slowdown in the TIS business in China. - FY2020-Q3RestatedAnnual report
「The market environment surrounding the global medical device industry is entering a period of transition, amid aging populations and efforts to contain healthcare spending in developed countries and economic development and population growth in emerging markets.」
Aging populations and healthcare cost containment in developed countries, and economic development and population growth in emerging markets, continue to be described as the market environment surrounding overseas operations. - FY2020-Q2RestatedAnnual report
「The market environment surrounding the global medical device industry is entering a period of transition, amid aging populations and efforts to contain healthcare spending in developed countries and economic development and population growth in emerging markets.」
Aging populations and healthcare cost containment in developed countries, and economic development and population growth in emerging markets, continue to be described as the market environment surrounding overseas operations. - FY2019WorsenedAnnual report
「Preparation costs associated with complying with the newly introduced European Medical Device Regulation (MDR)」
Regarding the risk of changes to overseas laws and regulations, preparation costs for compliance with the newly introduced European MDR became a specific burden for the following fiscal year. - FY2019-Q3RestatedAnnual report
「The market environment surrounding the global medical device industry is entering a period of transition, amid aging populations and efforts to contain healthcare spending in developed countries and economic development and population growth in emerging markets.」
Aging populations and healthcare cost containment in developed countries, and economic development and population growth in emerging markets, continue to be described as the market environment surrounding the global medical device industry. - FY2019-Q2RestatedAnnual report
「The market environment surrounding the global medical device industry is entering a period of transition, amid aging populations and efforts to contain healthcare spending in developed countries and economic development and population growth in emerging markets.」
Aging populations and healthcare cost containment in developed countries, and economic development and population growth in emerging markets, continue to be described as the market environment surrounding overseas operations. - FY2018-Q3RestatedAnnual report
「The market environment surrounding the global medical device industry is entering a period of transition, amid aging populations and efforts to contain healthcare spending in developed countries and economic development and population growth in emerging markets.」
Aging populations and healthcare cost containment in developed countries, and economic development and population growth in emerging markets, continue to be described as the market environment surrounding overseas operations. - FY2018-Q2RestatedAnnual report
「The market environment surrounding the global medical device industry is entering a period of transition, amid aging populations and efforts to contain healthcare spending in developed countries and economic development and population growth in emerging markets.」
Aging populations and healthcare cost containment in developed countries, and economic development and population growth in emerging markets, continue to be described as the market environment surrounding overseas operations. - FY2018-Q1RestatedAnnual report
「The market environment surrounding the global medical device industry is entering a period of transition, amid aging populations and efforts to contain healthcare spending in developed countries and economic development and population growth in emerging markets.」
Aging populations and healthcare cost containment in developed countries, and economic development and population growth in emerging markets, continue to be described as the market environment surrounding overseas operations. - FY2017-Q3RestatedAnnual report
「The market environment surrounding the global medical device industry is entering a period of transition, amid slower market growth and efforts to contain healthcare spending in developed countries and pricing pressure in emerging markets.」
Slower growth and healthcare cost containment in developed countries and pricing pressure in emerging markets are described as the market environment surrounding overseas operations. - FY2017-Q1MaterialisedAnnual report
「In Europe, following the outcome of the referendum in the United Kingdom, the decision was made to leave the European Union (EU), and its impact on the pharmaceutical and medical device industries is attracting attention.」
A specific event related to the risk of political changes in overseas markets occurred with the UK's decision to leave the EU. - FY2016First statedAnnual report
「The Company supplies products to more than 160 countries worldwide. However, an economic downturn in the various markets where it operates, a resulting contraction in demand, or unexpected political changes or amendments to laws and regulations in overseas countries could affect its operating results and financial condition.」
The breadth of its supply regions is presented as a foundation for growth, while demand, political conditions and regulatory changes in each region are disclosed as risks.